Drug profile · INN
oxymetazoline
DRIXINE
oxymetazoline (DRIXINE) is a adrenergic receptor alpha agonist. Associated with Lacuna Pharma Pty Ltd. Route of administration: topical. Current US regulatory status: approved.
Drug details — oxymetazoline
- US status
- approved
- Class
- —
- Route
- TOPICAL
- Patents
- 1
- Programs
- 8
- Data quality
- 0.89
Quick answer
oxymetazoline (DRIXINE) is a adrenergic receptor alpha agonist. Associated with Lacuna Pharma Pty Ltd. Route of administration: topical. Current US regulatory status: approved.
Key facts
Mechanism of action
Adrenergic receptor alpha agonist
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
| TGA | approved | — |
Pipeline programs
Related patents
Frequently asked questions
What is oxymetazoline?
oxymetazoline (DRIXINE) is a adrenergic receptor alpha agonist. Associated with Lacuna Pharma Pty Ltd. Route of administration: topical. Current US regulatory status: approved.
What is the brand name for oxymetazoline?
DRIXINE is a marketed brand name for oxymetazoline. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of oxymetazoline?
oxymetazoline has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.